Markus Wolschek
Chief Scientific Officer
Senior Scientist in vaccine lead candidate development, expert in process development and manufacturing.
More than 30 peer reviewed publications.
Markus Wolschek, co-founder and Chief Scientific Officer holds an Engineering degree in Biochemistry and Biotechnology and a PhD in Biochemistry and Biotechnology from the University of Technology, Vienna. As a Postdoc, he worked on non‐viral gene delivery systems and in oncology at the University of Vienna.
Markus has profound experience in virology and molecular biology and led biotech research groups at AVIR Green Hills Biotechnology as Vice President R&D. As CSO at BlueSky Immunotherapies, he is responsible for laboratory research activities, such as generating influenza vaccine strains by reverse genetics, the development of new immunotherapeutic viruses, process development and manufacturing, and assays supporting the clinical trials.
Markus has authored more than 30 peer‐reviewed publications in the fields of influenza virology and oncology and is inventor on several patents.